A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Upadacitinib (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms SELECT Axis 1
- Sponsors AbbVie
- 01 Sep 2017 Planned End Date changed from 8 Sep 2020 to 27 Sep 2020.
- 01 Sep 2017 Planned initiation date changed from 6 Aug 2017 to 25 Oct 2017.
- 09 Jun 2017 New trial record